Brief: Isofol Medical AB Says Receives FDA Fast Track Designation For Arfolitixorin In Advanced Colorectal Cancer (MCRC)
23/11/2021 17:47
Nov 23 (Reuters) - Isofol Medical AB (publ) ISOFOL.ST :
* ISOFOL MEDICAL AB (PUBL) RECEIVES FDA FAST TRACK
DESIGNATION FOR
ARFOLITIXORIN IN ADVANCED COLORECTAL CANCER (MCRC)
* ISOFOL MEDICAL AB - MARKET APPROVAL WITH FDA AND EMA,
WHICH
COULD RESULT IN A POTENTIAL COMMERCIALIZATION OF ARFOLITIXORIN
AS EARLY AS 2023
Source text for Eikon: ID:nWkr3PKvVQ
Further company coverage: ISOFOL.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Isofol Medical AB (publ)
See all newsSweden's Isofol Medical reports no Q2 revenue, net loss widens
Brief: Isofol Medical Q2 Net Income SEK -15.729 Million
Brief: Isofol Medical Adds Clinical Trial Sites To Phase Ib/Ii Arfolitixorin Study In Colorectal Cancer
Sweden's Isofol Medical Q1 net loss widens, raises funds
Brief: Isofol Medical Q1 Net Income SEK -15.062 Million